Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

The document reviews the application of contact immunotherapy, particularly with agents such as DNCB, DPCP, and SADBE, for treating a variety of skin conditions other than alopecia areata. It presents case reports and uncontrolled studies that suggest potential benefits in treating diseases like Merkel cell carcinoma, mycosis fungoides, atopic dermatitis, lichen nitidus, parapsoriasis, prurigo nodularis, systemic lupus erythematosus (SLE), and vitiligo. However, the evidence is limited, and there is a need for more controlled studies to establish efficacy and safety. The review also discusses the adverse effects and safety concerns associated with these treatments, including rare events and the mutagenic potential of DNCB. Despite these concerns, contact immunotherapy remains a cost-effective and convenient option, especially in developing countries and for patients who cannot use conventional therapies. The document emphasizes the need for further research to optimize treatment regimens and to better understand the mechanisms of action of contact immunotherapy. No new studies with human participants or animals were conducted by the authors of the article.